期刊文献+

Remission of type 2 diabetes mellitus

下载PDF
导出
摘要 The surge in type 2 diabetes mellitus(T2DM)is tightly linked to obesity,leading to ectopic fat accumulation in internal organs.Weight management has become a cornerstone of T2DM treatment,with evidence suggesting that significant weight loss can induce remission.Remission,defined as sustained hemoglobin(HbA1c)below 6.5% for at least 3 months without medication,can be achieved through various approaches,including lifestyle,medical,and surgical interventions.Metabolic bariatric surgery offers significant remission rates,particularly for patients with severe obesity.Intensive lifestyle modifications,including lowcalorie diets and exercise,have also demonstrated significant potential.Medications like incretin-based agents show robust results in improving beta-cell function,achieving glycemic control,and promoting weight loss.While complete remission without medication may not be attainable for everyone,especially those with severe insulin resistance or deficiency,early and aggressive glycemic control remains a crucial strategy.Maintaining HbA1c below 6.5%from the time of diagnosis reduces the risk of long-term complications and mortality.Moreover,considering a broader definition of remission,encompassing individuals with sustained control on medication,could offer a more comprehensive and inclusive approach to managing this chronic disease.
出处 《World Journal of Diabetes》 SCIE 2024年第7期1384-1389,共6页 世界糖尿病杂志(英文版)(电子版)
  • 相关文献

参考文献5

二级参考文献180

  • 1Aguiree F, Brown A, Cho NH, Dahlquist G, Dodd S, DunningT, Hirst M, Hwang C, Magliano D, Patterson C, Scott C, ShawJ, Soltesz G, Usher-Smith J, Whiting D. IDF Diabetes Atlas.IDF diabetes Atlas. 6th ed. Brussels, Belgium: InternationalDiabetes Federation, 2013. 被引量:1
  • 2Haffner SM, Lehto S, R-nnemaa T, Py-r-l- K, Laakso M.Mortality from coronary heart disease in subjects with type 2diabetes and in nondiabetic subjects with and without priormyocardial infarction. N Engl J Med 1998; 339: 229-234 [PMID:9673301 DOI: 10.1056/NEJM199807233390404]. 被引量:1
  • 3Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E,Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF,Holme I, Nj-lstad I, Fletcher A, Nilsson P, Lewington S,Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, HuFB, Danesh J. Diabetes mellitus, fasting glucose, and risk ofcause-specific death. N Engl J Med 2011; 364: 829-841 [PMID:21366474 DOI: 10.1056/NEJMoa1008862]. 被引量:1
  • 4Defronzo RA. Banting Lecture. From the triumvirate to theominous octet: a new paradigm for the treatment of type 2diabetes mellitus. Diabetes 2009; 58: 773-795 [PMID: 19336687]. 被引量:1
  • 5Kahn SE, Cooper ME, Del Prato S. Pathophysiology andtreatment of type 2 diabetes: perspectives on the past, present,and future. Lancet 2014; 383: 1068-1083 [PMID: 24315620 DOI:10.1016/S0140-6736(13)62154-6]. 被引量:1
  • 6Bergman RN, Phillips LS, Cobelli C. Physiologic evaluationof factors controlling glucose tolerance in man: measurementof insulin sensitivity and beta-cell glucose sensitivity fromthe response to intravenous glucose. J Clin Invest 1981; 68:1456-1467 [PMID: 7033284 DOI: 10.1172/JCI110398]. 被引量:1
  • 7Bergman RN, Ader M, Huecking K, Van Citters G. Accurateassessment of beta-cell function: the hyperbolic correction.Diabetes 2002; 51 Suppl 1: S212-S220 [PMID: 11815482 DOI:10.2337/diabetes.51.2007.S212]. 被引量:1
  • 8Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Betacellfunction is a major contributor to oral glucose tolerancein high-risk relatives of four ethnic groups in the U.S. Diabetes2002; 51: 2170-2178 [PMID: 12086947]. 被引量:1
  • 9DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologicapproach to therapy in patients with newly diagnosed type2 diabetes. Diabetes Care 2013; 36 Suppl 2: S127-S138 [PMID:23882037 DOI: 10.2337/dcS13-2011]. 被引量:1
  • 10Ichise M, Harris PE. Imaging of beta-cell mass and function. JNucl Med 2010; 51: 1001-1004 [PMID: 20554742 DOI: 10.2967/jnumed.109.068999]. 被引量:1

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部